Sera Prognostics vs YD Bio
YD Bio is the larger business, with $596,817 of revenue in fiscal 2025 against $81,000 for Sera Prognostics (7.4 times as much). YD Bio grew faster (16.9% against 5.2%). YD Bio kept more of each dollar of sales as profit: a net margin of -1392.6% against -39417.3%.
| Latest fiscal year | Sera PrognosticsSERA, 2025 | YD BioYDES, 2025 |
|---|---|---|
| Revenue | $81,000 | $596,817 |
| Revenue growth | 5.2% | 16.9% |
| Net income | −$31.9m | −$8.3m |
| Operating margin | -45066.7% | -883.3% |
| Net margin | -39417.3% | -1392.6% |
| Return on equity | -51.8% | — |
| Free cash flow | −$26.3m | −$8.0m |
| Cash | $3.9m | $6.0m |
| Total debt | $0 | $6,764 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 72 | — |
| Market value | $102m | $446m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 0 buys, 52 sales | 3 buys, 0 sales |